Chk1 inhibitors have been shown to be effective against mouse models Myc-driven malignancies, such as B-cell lymphoma [29], and Wee1 inhibitors enhance the efficacy of the SRC inhibitors in Burkitt lymphomas [30]. Here, MYC is linked to Burkitt lymphoma.